首页> 美国卫生研究院文献>BMJ Open >Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

【2h】

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

机译：贝伐单抗联合厄洛替尼与单独使用贝伐单抗或厄洛替尼治疗非小细胞肺癌的疗效和安全性：系统评价和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesBevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However, the efficacy of bevacizumab in combination with erlotinib remains controversial. Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC.

机译：目的贝伐单抗和厄洛替尼抑制不同的肿瘤生长途径，并且在非小细胞肺癌（NSCLC）的治疗中均显示出有益的作用。但是，贝伐单抗联合厄洛替尼的疗效仍存在争议。因此，我们进行了荟萃分析，比较了贝伐单抗和厄洛替尼的联合治疗与贝伐单抗或厄洛替尼单药治疗非小细胞肺癌的比较。

著录项

期刊名称 BMJ Open
作者
Shu Zhang; Xiao-dong Mao; Hai-tao Wang; Feng Cai; Jing Xu;
展开▼
作者单位

展开▼
年(卷),期 2016(6),6
年度 2016
页码 e011714
总页数 10
原文格式 PDF
正文语种
中图分类
关键词
bevacizumab erlotinib non-small cell lung cancer meta-analysis;

机译：贝伐单抗;厄洛替尼;非小细胞肺癌;荟萃分析;

相似文献

外文文献
中文文献
专利

1. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. [J] . Herbst RS, Ansari R, Bustin F, The Lancet . 2011,第9780期

机译：在标准一线化疗失败后，Bevacizumab Plus erlotinib与orlotinib对orlotinib的疗效在预测的非小细胞肺癌中（beta）：双盲，安慰剂控制，第3期试验。
2. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. [J] . Herbst RS, Ansari R, Bustin F, The Lancet . 2011,第9780期

机译：标准一线化疗（BeTa）失败后，贝伐单抗联合厄洛替尼与单独使用厄洛替尼在晚期非小细胞肺癌中的疗效：一项双盲，安慰剂对照的3期试验。
3. EFFICACY AND SAFETY OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN ASIAN PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS [J] . Hyderboini R. K., Vsn M., Chidirala S. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Bevacizumab Plus化疗与化疗在亚洲患者中非小细胞肺癌治疗中的疗效和安全性：系统审查和荟萃分析
4. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis [O] . Shiqian Han, Yuanduo Hong, Tingting Liu, 2018

机译：紫杉醇和卡铂联合贝伐珠单抗与非贝伐单抗相比非小细胞肺癌的疗效和安全性：系统评价和荟萃分析
7. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis [O] . Shu Zhang, Xiao-dong Mao, Hai-tao Wang, 2016

机译：Bevacizumab Plus erlotinib与贝伐单抗或欧洲毒素的疗效和安全性在治疗非小细胞肺癌中的疗效和安全性：系统审查和荟萃分析

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

摘要

著录项

相似文献

相关主题

期刊订阅